Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMRVNS 20-002: Lot-to-lot Consistency and Immunogenicity of Investigational MMRV Vaccine in Children
NCT07742644Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 6
01
Overview
A Phase 3 trial of MMRVNS in measles, mumps, rubella, varicella (VZV), sponsored by GSK. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
MMRVNS
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT07742644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742644.